Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...

One of the hottest growth areas in the healthcare landscape these days is the obesity drug market because of a class of drugs ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

Intel Corporation (INTC) shares surged 9.3% on takeover speculation following its CEO's December departure. Novo Nordisk A/S (NVO) shares fell 5.3% after Medicare included semaglutide, the key ...

A new study highlighted Monday the potential benefits of popular diabetes drugs on a wide range of health issues including dementia and cardiovascular diseases, although experts warned against seeing ...

When children with obesity undergo weight-loss treatment, the effects have repercussions later in life and the risk of serious health problems and premature death is lower as they reach young ...

Viking (VKTX) is in the midst of a phase 2a dosing trial of its oral obesity drug VK2735, with a data readout expected in the second half of the year. The company is expected to launch a phase 3 trial ...

CFRA analyst Wan Nurhayati revised the price target for Novo Nordisk (NYSE:NVO) shares, reducing it to $90 from the previous target of $122. Despite the price target cut, the analyst retained a Hold ...

Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're ...

Danish offshore wind giant Orsted faced a fresh stock market hammering on Tuesday after the group announced a new ...

McKesson's stock appears undervalued, trading at 18 times forward earnings and free cash flow. See why MCK is a Hold.

From Alzheimer's prevention to weight-loss dominance, Novo bets on innovation and share repurchases amid Medicare pressure.